Clinical Trial Update: NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for NP-101 (TQ Formula) in combination with nivolumab and ipilimumab for advanced or metastatic extra-pulmonary neuroendocrine car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Neoplasm
• Gastroenteropancreatic Neuroendocrine Tumor
• Mixed Neuroendocrine-non-neuroendocrine Neoplasm
• Neuroendocrine Carcinoma

Drugs mentioned

• NP-101 (TQ Formula)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Amr Mohamed MD | Conditions: Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 1 | Status: ACTIVE_NOT_RECRUITING